Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-AAT in healthy adult volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ARO-AAT | Active Comparator |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ARO-AAT Injection | Drug | Single or multiple doses of ARO-AAT by subcutaneous (sc) injections |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events (AEs) Possibly or Probably Related to Treatment | Part A (single-ascending dose [SAD] phase): up to 29 (+/- 2) days post-dose; Part B (multiple-ascending dose [MAD] phase): up to 113 (+/- 2) days post-dose |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (PK) of ARO-AAT: Maximum Observed Plasma Concentration (Cmax) | Part A (single-ascending dose [SAD] phase): up to 48 hours post-dose; Part B (multiple-ascending dose [MAD] phase): up to 48 hours post-dose | |
| PK of ARO-AAT: Time to Maximum Plasma Concentration (Tmax) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
NOTE: additional inclusion/exclusion criteria may apply, per protocol
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site 1 | Grafton | Auckland | 1010 | New Zealand |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019896 | alpha 1-Antitrypsin Deficiency |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sterile Normal Saline (0.9% NaCl) |
| Other |
Calculated volume to match active comparator |
|
| Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose |
| PK of ARO-AAT: Terminal Elimination Half-Life (t½) | Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose |
| PK of ARO-AAT: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) | Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose |
| PK of ARO-AAT: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf) | Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose |
| Percent Change in Serum Alpha-1 Antitrypsin (AAT) Levels From Day 1 Pre-Dose Baseline to Nadir | Part A (SAD phase): up to 29 (+/- 2) days; Part B (MAD phase): up to 113 (+/- 2) days |
| Duration of Response of Serum AAT levels From Nadir Back to Above 20% of Baseline or Above 90 mg/dL | Part A (SAD phase): up to 29 (+/- 2) days; Part B (MAD phase): up to 113 (+/- 2) days |
| D030342 |
| Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D013352 | Subcutaneous Emphysema |
| D004646 | Emphysema |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |